There is no evidence that digital pills, prescription medications with ingestible wireless sensors, are beneficial to patients and, in fact, the technology poses a danger to the provider-patient relationship.
That’s the contention of researchers at the University of Illinois at Chicago who caution that, despite the Food and Drug Administration’s 2017 approval of the first drug in the U.S. with a digital ingestion tracking system, it is premature for providers to allow this new tool into clinical settings.
